Timothy Eugene Sullivan Sells 1,730 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan sold 1,730 shares of Apellis Pharmaceuticals stock in a transaction on Friday, January 17th. The shares were sold at an average price of $29.96, for a total transaction of $51,830.80. Following the completion of the transaction, the chief financial officer now owns 86,370 shares in the company, valued at approximately $2,587,645.20. This trade represents a 1.96 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Timothy Eugene Sullivan also recently made the following trade(s):

• On Monday, January 13th, Timothy Eugene Sullivan sold 2,170 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $28.70, for a total transaction of $62,279.00.

Apellis Pharmaceuticals Trading Up 0.6 %

Shares of NASDAQ APLS traded up $0.19 during midday trading on Tuesday, reaching $30.13. 1,461,289 shares of the stock were exchanged, compared to its average volume of 2,274,031. The stock has a 50 day moving average price of $31.89 and a 200-day moving average price of $33.31. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The company has a market capitalization of $3.75 billion, a P/E ratio of -14.84 and a beta of 0.94. Apellis Pharmaceuticals, Inc. has a 52-week low of $24.34 and a 52-week high of $71.90.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm had revenue of $196.83 million during the quarter, compared to analysts’ expectations of $200.00 million. During the same period in the previous year, the firm posted ($1.17) earnings per share. The firm’s revenue was up 78.3% on a year-over-year basis. Equities research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.71 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Needham & Company LLC lowered their price objective on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Piper Sandler dropped their price objective on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a report on Wednesday, November 6th. Citigroup reduced their target price on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Robert W. Baird lowered their price target on shares of Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a research note on Thursday, November 7th. Finally, William Blair assumed coverage on shares of Apellis Pharmaceuticals in a research note on Wednesday, October 16th. They issued an “outperform” rating for the company. Eight equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.71.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in APLS. HighVista Strategies LLC boosted its stake in Apellis Pharmaceuticals by 4.1% in the 2nd quarter. HighVista Strategies LLC now owns 7,566 shares of the company’s stock worth $290,000 after buying an additional 300 shares during the last quarter. Amalgamated Bank lifted its holdings in shares of Apellis Pharmaceuticals by 5.4% during the 2nd quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock worth $268,000 after acquiring an additional 359 shares during the period. KBC Group NV boosted its position in shares of Apellis Pharmaceuticals by 34.8% in the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after acquiring an additional 679 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Apellis Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after purchasing an additional 781 shares during the period. Finally, Wolverine Asset Management LLC acquired a new position in Apellis Pharmaceuticals during the third quarter worth approximately $27,000. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).